# A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

Source: https://onco.cc/trials/nct04730258/  
OnCo record `nct04730258` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Azacitidine in chronic myelomonocytic leukaemia and mds/mpn overlap neoplasms, run by Treadwell Therapeutics, Inc, active and no longer recruiting.

## Summary

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML is a phase 1/2 interventional study registered as NCT04730258 by Treadwell Therapeutics, Inc, with 72 participants planned, started 2021-04-16 and due to reach its primary completion in 2026-01. Interventions recorded: CFI-400945, Azacitidine. Conditions listed: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04730258
- Phase: 1/2
- Setting: Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML
- Sponsor: Treadwell Therapeutics, Inc
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT04730258: https://clinicaltrials.gov/study/NCT04730258

## Connected records

- cancers: [Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms](https://onco.cc/cancers/cmml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04730258.json